Advertisement

Pneumo News

, Volume 11, Issue 6, pp 35–42 | Cite as

Behandlung IgE-vermittelter Erkrankungen

Spezifische Immuntherapie bei Allergien

  • Faustina FunkeEmail author
  • Christian Taube
cme fortbildung
  • 169 Downloads

Zusammenfassung

Allergische Erkrankungen nehmen an Ausmaß und Bedeutung zu. Die spezifische Immuntherapie — auch allergische Immuntherapie genannt — ist bisher die einzige kausale Behandlung für Patienten mit IgE-vermittelter Krankheit wie der allergischen Rhinokonjunktivitis. Verfügbar sind subkutane und sublinguale Applikationen. Neben der Verminderung der Symptomlast gibt es auch immer mehr Hinweise für einen Langzeiteffekt der Therapie.

Literatur

  1. 1.
    Ege MJ, Mayer M, Normand AC et al. Exposure to environmental microorganisms and childhood asthma. N Eng J Med. 2011;364(8):701–9CrossRefGoogle Scholar
  2. 2.
    Stein MM, Hrusch CL, Gozdz J et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Eng J Med. 2016;375(5):411–21CrossRefGoogle Scholar
  3. 3.
    Noon, L Prophylactic inoculation against hay fever. Lancet. 1911;1:1572–3CrossRefGoogle Scholar
  4. 4.
    Pfaar O, Bachert C, Bufe A et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282–319CrossRefGoogle Scholar
  5. 5.
    Bellinghausen, I, Metz G, Enk AH et al. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol. 1997;27(5):1131–9CrossRefGoogle Scholar
  6. 6.
    Barzaghi F, Passerini L, Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol. 2012;3:211CrossRefGoogle Scholar
  7. 7.
    Bacher P, Scheffold A. New technologies for monitoring human antigen-specific T cells and regulatory T cells by flow-cytometry. Curr Opinion in Pharm. 2015;23:17–24CrossRefGoogle Scholar
  8. 8.
    Bacher P, Heinrich F, Stervbo U et al. Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans. Cell. 2016;167(4):1067–78.e16CrossRefGoogle Scholar
  9. 9.
    Norman PS, Van Metre TE The safety of allergenic immunotherapy. J Allergy Clin Immunol. 1990;85(2):522–5CrossRefGoogle Scholar
  10. 10.
    Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123(1):167–173.e7CrossRefGoogle Scholar
  11. 11.
    Dhami S, Zaman H, Varga EM et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy. 2017;72(3):342–65CrossRefGoogle Scholar
  12. 12.
    Sturm GJ, Varga EM, Roberts G et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018;73(4):744–64CrossRefGoogle Scholar
  13. 13.
    Dhami S, Nurmatov U, Arasi S et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017;72(11):1597–631CrossRefGoogle Scholar
  14. 14.
    Roberts G, Pfaar O, Akdis CA et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–98CrossRefGoogle Scholar
  15. 15.
    Dhami S, Kakourou A, Asamoah F et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017;72(12):1825–48CrossRefGoogle Scholar
  16. 16.
    Virchow JC, Backer V, Kuna P et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA. 2016;315(16):1715–25CrossRefGoogle Scholar
  17. 17.
    Klimek L, Pfaar O, Worm M. New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs). Expert Rev Clin Immunol. 2016:1–13Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Universitätsmedizin Essen, Ruhrlandklinik, Klinik für Pneumologie, Westdeutsches Lungenzentrum am Universitätsklinikum EssenEssenDeutschland

Personalised recommendations